

PRESS INFORMATION

Additional information regarding yesterday's voting rights announcement

Munich, 17 September 2008. The Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) yesterday released a voting rights announcement for European distribution in accordance with Section 26 of the German Securities Trading Act.

The announcement was published because the shares in divieni Verwaltungs GmbH were transferred from Prof. Dr. Christof Hettich and Dr. Friedrich von Bohlen und Halbach to divieni Hopp BioTech holding GmbH & Co. KG, which made an announcement under the German Securities Trading Act to both the German Federal Financial Supervisory Authority (BaFin) and WILEX AG necessary.

WILEX AG has not been notified that the 28.52% share held by divieni Hopp BioTech GmbH & Co. KG has changed or that a share in voting rights has exceeded or fallen below any threshold.

About WILEX

WILEX is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. WILEX's mission is to develop drugs and diagnostic agents with a low side effect profile and targeted treatment of different types of cancer as well as for early detection of tumours. The Company's product candidates are based on antibodies and small molecules. WILEX has an attractive product pipeline which includes both drug and diagnostic candidates: The substances RENCAREX[®] and REDECTANE[®] are currently undergoing a Phase III registration trial. The substance MESUPRON[®] is currently in a Phase II programme. Based on this pipeline, WILEX's aim is to achieve profitability within a few years through the consistent commercialisation of its products and in the long term to finance its research and development programmes from its operating business.

Website: <http://www.wilex.com>

ISIN DE0006614720 / WKN 661472 / Symbol WL6

Contact

WILEX AG
Grillparzerstr. 10
D-81675 Munich
Germany
Website: <http://www.wilex.com>

Public Relations

Juliane Giese

Manager Public Relations
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
E-mail: press@wilex.com

Investor Relations

Katja Arnold (CIRO)
Manager Investor Relations
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors@wilex.com

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.